TCWP’s Vertex Pharmaceuticals VRTX Stock Holding History

TCWP’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-23,964	Closed	-$6.25M	–	1712
2022 Q1	$6.25M	Buy	+23,964	New	+$5.69M	1.14%	16

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

TCWP's VRTX Position: Q2 2022 in Review

TCWP sold out of Vertex Pharmaceuticals (VRTX) in Q2 2022, closing a stake of 23,964 shares — an estimated $6.25M sold.

TCWP first reported a position in VRTX in Q1 2022 and held it in 1 quarter. The position peaked at $6.25M in Q1 2022. 1,106 funds tracked by Wall St. Rank hold VRTX as of Q2 2022.

TCWP reported no remaining Vertex Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
TCWP sold 23,964 Vertex Pharmaceuticals shares in Q2 2022, an estimated $6.25M.
TCWP first reported a position in Vertex Pharmaceuticals in Q1 2022 and held it in 1 quarter.
TCWP's Vertex Pharmaceuticals position peaked at $6.25M in Q1 2022.
1,106 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2022.

Based on TCWP's 13F filing for Q2 2022, filed 15 Aug 2022.